B. Thürlimann

4P Predicting triple-negative breast cancer molecular subtype from hematoxylin and eosin using deep neural networks

N. Occelli, David Venet, Alejandro J. Garcia, S. Majjaj et autres

be, it, ch, au, us, hu (code pays fourni par la source)

Abstract GS6-01: Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy

Ivana Šestak, MM Regan, Andrew Dodson, G. Viale et autres

ch, gb, us, it (code pays fourni par la source)

Abstract P4-12-01: Independent validation of EarlyR gene signature in BIG 1-98: A randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer

Steven Buechler, KP Gray, Yesim Gökmen‐Polar, Scooter Willis et autres

us, ch (code pays fourni par la source)

Abstract PD1-03: Cholesterol, cholesterol lowering medication use, and breast cancer outcomes in the BIG 1-98 study

Signe Borgquist, Anita Giobbie‐Hurder, Thomas P. Ahern, JE Garber et autres

us, ch (code pays fourni par la source)

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)(vol 26, pg 873, 2015)

S. Gourgou-Bourgade, Davecia Ragoonath Cameron, P Poortmans, B Asselain et autres

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

S. Gourgou-Bourgade, David Cameron, P. Poortmans, Bernard Asselain et autres

in, fr, gb, nl, pt, be, si, dk, it, ch, de (code pays fourni par la source)

Prevention of Symptomatic Skeletal Events with Denosumab Administered Every 4 Weeks Versus Every 12 Weeks–A Non-Inferiority Phase III Trial: Sakk 96/12 - Reduse

Arnoud J. Templeton, Lukas Stalder, L. Albiges Sauvin, J. Bernhard et autres

ch, fr (code pays fourni par la source)

ESR1 and ESR2 polymorphisms in BIG 1−98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence for early breast cancer.

Mark Bouzyk, Kathryn P. Gray, Meredith M. Regan, Olivia Pagani et autres

Bone mineral density (BMD) in participants (pts) of trial BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence.

Andrea De Censi, Zheng Sun, B. Thürlimann, Chris McIntosh et autres

Symptoms of endocrine treatment and outcome: A retrospective analysis of the monotherapy arms of the BIG 1-98 trial.

J. Huober, B. F. Cole, Anita Giobbie‐Hurder, Manuela Rabaglio et autres

Modelling Bone Mineral Density in Swiss Breast Cancer Patients Treated with Letrozole, Tamoxifen and Sequences of Letrozole and Tamoxifen in the BIG 1-98 Study (SAKK 21/07).

Khalil Zaman, B. Thürlimann, J. Huober, A. Schönenberger et autres

ch, us (code pays fourni par la source)

Contents, Vol. 19, No. 2, 1996

Frank Hartmann, G. Kornek, D. Depisch, G. Salem et autres